Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
102 articles with Adicet Bio, Inc.
-
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
12/2/2022
Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022
12/1/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on November 30, 2022.
-
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
11/30/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.
-
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
11/29/2022
Adicet Bio, Inc. today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer.
-
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/8/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2022.
-
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/7/2022
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
11/3/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL) was made available as part of the 64th American Society of Hematology (ASH) Annual Meeting.
-
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
11/1/2022
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will present at the 2022 Jefferies London Healthcare Conference being held from November 15-17, 2022 in London.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 31, 2022
10/31/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on October 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to 12 individuals hired by Adicet in October 2022.
-
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/5/2022
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 01, 2022
10/1/2022
Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.
-
Adicet Bio to Present at Upcoming September 2022 Investor Conferences
9/7/2022
Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in September.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2022
8/31/2022
Adicet Bio, Inc. announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022.
-
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/10/2022
Adicet Bio, Inc. today reported financial results and operational highlights for the second quarter ended June 30, 2022.
-
Adicet Bio to Present at Upcoming Investor Conferences
8/1/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 29, 2022
7/29/2022
Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on July 29, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to seven individuals hired by Adicet in July 2022.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on June 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to ten individuals hired by Adicet in June 2022.
-
Adicet Bio to Present at Upcoming Investor Conferences - June 21, 2022
6/21/2022
Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in June.
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
-
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
6/6/2022
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL), as of May 31, 2022 data-cut date.